|
1
|
Navarro Gras A, Björklund AT and Chekenya
M: Therapeutic potential and challenges of natural killer cells in
treatment of solid tumors. Front Immunol. 6:2022015.PubMed/NCBI
|
|
2
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bauer S, Groh V, Wu J, Steinle A, Phillips
JH, Lanier LL and Spies T: Activation of NK cells and T cells by
NKG2D, a receptor for stress-inducible MICA. Science. 285:727–729.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raulet DH and Guerra N: Oncogenic stress
sensed by the immune system: Role of natural killer cell receptors.
Nat Rev Immunol. 9:568–580. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lanier LL: NKG2D receptor and its ligands
in host defense. Cancer Immunol Res. 3:575–582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gasser S, Orsulic S, Brown EJ and Raulet
DH: The DNA damage pathway regulates innate immune system ligands
of the NKG2D receptor. Nature. 436:1186–1190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fine JH, Chen P, Mesci A, Allan DS, Gasser
S, Raulet DH and Carlyle JR: Chemotherapy-induced genotoxic stress
promotes sensitivity to natural killer cell cytotoxicity by
enabling missing-self recognition. Cancer Res. 70:7102–7113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soriani A, Zingoni A, Cerboni C, Iannitto
ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C,
Petrucci MT, Guarini A, et al: ATM-ATR-dependent up-regulation of
DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic
agents results in enhanced NK-cell susceptibility and is associated
with a senescent phenotype. Blood. 113:3503–3511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shibata A and Jeggo PA: DNA double-strand
break repair in a cellular context. Clin Oncol. 26:243–249. 2014.
View Article : Google Scholar
|
|
11
|
Shiloh Y: ATM and related protein kinases:
Safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rhind N: Changing of the guard: How ATM
hands off DNA double-strand break signaling to ATR. Mol Cell.
33:672–674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shinkai Y and Tachibana M: H3K9
methyltransferase G9a and the related molecule GLP. Genes Dev.
25:781–788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Melcher M, Schmid M, Aagaard L, Selenko P,
Laible G and Jenuwein T: Structure-function analysis of SUV39H1
reveals a dominant role in heterochromatin organization, chromosome
segregation, and mitotic progression. Mol Cell Biol. 20:3728–3741.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tachibana M, Sugimoto K, Fukushima T and
Shinkai Y: Set domain-containing protein, G9a, is a novel
lysine-preferring mammalian histone methyltransferase with
hyperactivity and specific selectivity to lysines 9 and 27 of
histone H3. J Biol Chem. 276:25309–25317. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clayton A, Mitchell JP, Court J, Linnane
S, Mason MD and Tabi Z: Human tumor-derived exosomes down-modulate
NKG2D expression. J Immunol. 180:7249–7258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shibata A, Moiani D, Arvai AS, Perry J,
Harding SM, Genois MM, Maity R, van Rossum-Fikkert S, Kertokalio A,
Romoli F, et al: DNA double-strand break repair pathway choice is
directed by distinct MRE11 nuclease activities. Mol Cell. 53:7–18.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakajima NI, Hagiwara Y, Oike T, Okayasu
R, Murakami T, Nakano T and Shibata A: Pre-exposure to ionizing
radiation stimulates DNA double strand break end resection,
promoting the use of homologous recombination repair. PLoS One.
10:e01225822015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Groh V, Rhinehart R, Secrist H, Bauer S,
Grabstein KH and Spies T: Broad tumor-associated expression and
recognition by tumor-derived gamma delta T cells of MICA and MICB.
Proc Natl Acad Sci USA. 96:6879–6884. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diefenbach A and Raulet DH: Strategies for
target cell recognition by natural killer cells. Immunol Rev.
181:170–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pende D, Rivera P, Marcenaro S, Chang CC,
Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, et
al: Major histocompatibility complex class I-related chain A and
UL16-binding protein expression on tumor cell lines of different
histotypes: Analysis of tumor susceptibility to NKG2D-dependent
natural killer cell cytotoxicity. Cancer Res. 62:6178–6186.
2002.PubMed/NCBI
|
|
22
|
Deckbar D, Jeggo PA and Löbrich M:
Understanding the limitations of radiation-induced cell cycle
checkpoints. Crit Rev Biochem Mol Biol. 46:271–283. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shibata A, Conrad S, Birraux J, Geuting V,
Barton O, Ismail A, Kakarougkas A, Meek K, Taucher-Scholz G,
Löbrich M, et al: Factors determining DNA double-strand break
repair pathway choice in G2 phase. EMBO J. 30:1079–1092. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmid TE, Dollinger G, Beisker W, Hable
V, Greubel C, Auer S, Mittag A, Tarnok A, Friedl AA, Molls M, et
al: Differences in the kinetics of gamma-H2AX fluorescence decay
after exposure to low and high LET radiation. Int J Radiat Biol.
86:682–691. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jazayeri A, Falck J, Lukas C, Bartek J,
Smith GC, Lukas J and Jackson SP: ATM- and cell cycle-dependent
regulation of ATR in response to DNA double-strand breaks. Nat Cell
Biol. 8:37–45. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rothkamm K, Krüger I, Thompson LH and
Löbrich M: Pathways of DNA double-strand break repair during the
mammalian cell cycle. Mol Cell Biol. 23:5706–5715. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kato N, Tanaka J, Sugita J, Toubai T,
Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M, et al:
Regulation of the expression of MHC class I-related chain A, B
(MICA, MICB) via chromatin remodeling and its impact on the
susceptibility of leukemic cells to the cytotoxicity of
NKG2D-expressing cells. Leukemia. 21:2103–2108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raneros Baragaño A, Martín-Palanco V,
Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C and
Suarez-Alvarez B: Methylation of NKG2D ligands contributes to
immune system evasion in acute myeloid leukemia. Genes Immun.
16:71–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baylin SB: DNA methylation and gene
silencing in cancer. Nat Clin Pract Oncol. 2:(Suppl 1). S4–S11.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Skov S, Pedersen MT, Andresen L, Straten
PT, Woetmann A and Odum N: Cancer cells become susceptible to
natural killer cell killing after exposure to histone deacetylase
inhibitors due to glycogen synthase kinase-3-dependent expression
of MHC class I-related chain A and B. Cancer Res. 65:11136–11145.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Armeanu S, Bitzer M, Lauer UM, Venturelli
S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et
al: Natural killer cell-mediated lysis of hepatoma cells via
specific induction of NKG2D ligands by the histone deacetylase
inhibitor sodium valproate. Cancer Res. 65:6321–6329. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diermayr S, Himmelreich H, Durovic B,
Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J,
Gratwohl A, Tichelli A, Paluszewska M, et al: NKG2D ligand
expression in AML increases in response to HDAC inhibitor valproic
acid and contributes to allorecognition by NK-cell lines with
single KIR-HLA class I specificities. Blood. 111:1428–1436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung H, Hsiung B, Pestal K, Procyk E and
Raulet DH: RAE-1 ligands for the NKG2D receptor are regulated by
E2F transcription factors, which control cell cycle entry. J Exp
Med. 209:2409–2422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dokmanovic M, Clarke C and Marks PA:
Histone deacetylase inhibitors: Overview and perspectives. Mol
Cancer Res. 5:981–989. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Su H, Altucci L and You Q: Competitive or
noncompetitive, that's the question: Research toward histone
deacetylase inhibitors. Mol Cancer Ther. 7:1007–1012. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Avallone A, Piccirillo MC, Delrio P,
Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C,
Cavalcanti E, et al: Phase 1/2 study of valproic acid and
short-course radiotherapy plus capecitabine as preoperative
treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic
acid - short Radiotherapy - rectum 3rd trial). BMC Cancer.
14:8752014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Krug LM, Kindler HL, Calvert H, Manegold
C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K,
et al: Vorinostat in patients with advanced malignant pleural
mesothelioma who have progressed on previous chemotherapy
(VANTAGE-014): A phase 3, double-blind, randomised,
placebo-controlled trial. Lancet Oncol. 16:447–456. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gaszner M and Felsenfeld G: Insulators:
Exploiting transcriptional and epigenetic mechanisms. Nat Rev
Genet. 7:703–713. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
West AC and Johnstone RW: New and emerging
HDAC inhibitors for cancer treatment. J Clin Invest. 124:30–39.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miller KM, Tjeertes JV, Coates J, Legube
G, Polo SE, Britton S and Jackson SP: Human HDAC1 and HDAC2
function in the DNA-damage response to promote DNA nonhomologous
end-joining. Nat Struct Mol Biol. 17:1144–1151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Blattmann C, Oertel S, Thiemann M, Dittmar
A, Roth E, Kulozik AE, Ehemann V, Weichert W, Huber PE, Stenzinger
A, et al: Histone deacetylase inhibition sensitizes osteosarcoma to
heavy ion radiotherapy. Radiat Oncol. 10:1462015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim JH, Shin JH and Kim IH: Susceptibility
and radiosensitization of human glioblastoma cells to trichostatin
A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys.
59:1174–1180. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cornelissen B, Kersemans V, Darbar S,
Thompson J, Shah K, Sleeth K, Hill MA and Vallis KA: Imaging DNA
damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer
Res. 71:4539–4549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Munshi A, Kurland JF, Nishikawa T, Tanaka
T, Hobbs ML, Tucker SL, Ismail S, Stevens C and Meyn RE: Histone
deacetylase inhibitors radiosensitize human melanoma cells by
suppressing DNA repair activity. Clin Cancer Res. 11:4912–4922.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
West AC, Smyth MJ and Johnstone RW: The
anticancer effects of HDAC inhibitors require the immune system.
Oncoimmunology. 3:e274142014. View Article : Google Scholar : PubMed/NCBI
|
